{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:49:56Z","timestamp":1777394996500,"version":"3.51.4"},"reference-count":47,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2017,8,29]],"date-time":"2017-08-29T00:00:00Z","timestamp":1503964800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2017,8,29]]},"DOI":"10.3233\/jad-170129","type":"journal-article","created":{"date-parts":[[2017,8,8]],"date-time":"2017-08-08T11:42:12Z","timestamp":1502192532000},"page":"283-293","source":"Crossref","is-referenced-by-count":72,"title":["PET Tau and Amyloid-\u03b2 Burden in Mild Alzheimer\u2019s Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers"],"prefix":"10.1177","volume":"60","author":[{"given":"Ivan","family":"Koychev","sequence":"first","affiliation":[{"name":"Department of Psychiatry, University of Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the Deep and Frequent Phenotyping study team (http:\/\/www.dementiastudy.co.uk\/)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger N.","family":"Gunn","sequence":"additional","affiliation":[{"name":"IMANOVA, Ltd"},{"name":"Department of Medicine, Imperial College, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azadeh","family":"Firouzian","sequence":"additional","affiliation":[{"name":"IMANOVA, Ltd"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Lawson","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Zamboni","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Basil","family":"Ridha","sequence":"additional","affiliation":[{"name":"NIHR Queen Square Dementia Biomedical Research Unit, University College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara J.","family":"Sahakian","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Cambridge, Cambridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James B.","family":"Rowe","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, University of Cambridge, UK and MRC Cognition and Brain Sciences Unit, Cambridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Thomas","sequence":"additional","affiliation":[{"name":"Institute of Neuroscience, Newcastle University, Newcastle, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynn","family":"Rochester","sequence":"additional","affiliation":[{"name":"Institute of Neuroscience, Newcastle University, Newcastle, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominic","family":"Ffytche","sequence":"additional","affiliation":[{"name":"King\u2019s College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Howard","sequence":"additional","affiliation":[{"name":"Department of Molecular Neuroscience, University College London Institute of Neurology, Queen Square, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[{"name":"Department of Molecular Neuroscience, University College London Institute of Neurology, Queen Square, London, UK"},{"name":"UK Dementia Research Institute, London, UK"},{"name":"Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M\u00f6lndal, Sweden"},{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, M\u00f6lndal, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clare","family":"MacKay","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Lovestone","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-170129_ref1","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","article-title":"Imaging brain amyloid in Alzheimer\u2019s disease with Pittsburgh Compound-B","volume":"55","author":"Klunk","year":"2004","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-170129_ref2","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1093\/brain\/awq277","article-title":"Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer\u2019s disease","volume":"133","author":"Jack","year":"2010","journal-title":"Brain"},{"key":"10.3233\/JAD-170129_ref3","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1212\/WNL.0b013e318212015e","article-title":"Amyloid PET imaging in patients with mild cognitive impairment: A 2-year follow-up study","volume":"76","author":"Koivunen","year":"2011","journal-title":"Neurology"},{"key":"10.3233\/JAD-170129_ref4","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1212\/WNL.0b013e3181b23564","article-title":"Conversion of amyloid positive and negative MCI to AD over 3 years: An 11C-PIB PET study","volume":"73","author":"Okello","year":"2009","journal-title":"Neurology"},{"key":"10.3233\/JAD-170129_ref5","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Doody","year":"2014","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-170129_ref6","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-170129_ref7","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1093\/brain\/aws327","article-title":"Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer\u2019s disease","volume":"136","author":"Lehmann","year":"2013","journal-title":"Brain"},{"key":"10.3233\/JAD-170129_ref8","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/brain\/awp326","article-title":"Increased metabolic vulnerability in early-onset Alzheimer\u2019s disease is not related to amyloid burden","volume":"133","author":"Rabinovici","year":"2010","journal-title":"Brain"},{"key":"10.3233\/JAD-170129_ref9","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jalz.2011.07.003","article-title":"Amyloid imaging in dementias with atypical presentation","volume":"8","author":"Wolk","year":"2012","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-170129_ref10","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/ene.12761","article-title":"Regional beta-amyloid burden does not correlate with cognitive or language deficits in Alzheimer\u2019s disease presenting as aphasia","volume":"23","author":"Jung","year":"2016","journal-title":"Eur J Neurol"},{"key":"10.3233\/JAD-170129_ref11","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1212\/WNL.0b013e31825dce28","article-title":"Early-onset Alzheimer disease clinical variants: Multivariate analyses of cortical thickness","volume":"79","author":"Ridgway","year":"2012","journal-title":"Neurology"},{"key":"10.3233\/JAD-170129_ref12","doi-asserted-by":"crossref","first-page":"e62471","DOI":"10.1371\/journal.pone.0062471","article-title":"FDG PET and MRI in logopenic primary progressive aphasia versus dementia of the Alzheimer\u2019s type","volume":"8","author":"Madhavan","year":"2013","journal-title":"PLoS One"},{"key":"10.3233\/JAD-170129_ref13","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s00401-013-1151-4","article-title":"Longitudinal change in CSF Tau and Abeta biomarkers for up to 48 months in ADNI","volume":"126","author":"Toledo","year":"2013","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JAD-170129_ref14","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1093\/brain\/awv199","article-title":"Alzheimer\u2019s disease cerebrospinal fluid biomarker in cognitively normal subjects","volume":"138","author":"Toledo","year":"2015","journal-title":"Brain"},{"key":"10.3233\/JAD-170129_ref15","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3389\/fneur.2015.00038","article-title":"PET imaging of tau pathology in Alzheimer\u2019s disease and tauopathies","volume":"6","author":"James","year":"2015","journal-title":"Front Neurol"},{"key":"10.3233\/JAD-170129_ref16","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S1474-4422(14)70252-2","article-title":"Tau imaging: Early progress and future directions","volume":"14","author":"Villemagne","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-170129_ref17","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/ana.24517","article-title":"Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue","volume":"78","author":"Marquie","year":"2015","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-170129_ref18","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jalz.2012.11.008","article-title":"[(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer\u2019s disease","volume":"9","author":"Xia","year":"2013","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-170129_ref19","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3233\/JAD-122059","article-title":"Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807","volume":"34","author":"Chien","year":"2013","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-170129_ref20","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/acn3.366","article-title":"[18F]AV-1451 PET in behavioral variant frontotemporal dementia due to MAPT mutation","volume":"3","author":"Bevan Jones","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"10.3233\/JAD-170129_ref21","first-page":"781","article-title":"18F-AV-1451 positron emission tomography in Alzheimer\u2019s disease and progressive supranuclear palsy","volume":"140","author":"Passamonti","year":"2017","journal-title":"Brain"},{"key":"10.3233\/JAD-170129_ref22","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/brain\/aww027","article-title":"Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer\u2019s disease","volume":"139","author":"Ossenkoppele","year":"2016","journal-title":"Brain"},{"key":"10.3233\/JAD-170129_ref23","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.neuron.2016.01.028","article-title":"PET imaging of tau deposition in the aging human brain","volume":"89","author":"Scholl","year":"2016","journal-title":"Neuron"},{"key":"10.3233\/JAD-170129_ref24","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/brain\/aww023","article-title":"Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages","volume":"139","author":"Schwarz","year":"2016","journal-title":"Brain"},{"key":"10.3233\/JAD-170129_ref25","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ana.20730","article-title":"Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans","volume":"59","author":"Fagan","year":"2006","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-170129_ref26","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/archneur.64.3.noc60123","article-title":"Cerebrospinal fluid tau\/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults","volume":"64","author":"Fagan","year":"2007","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-170129_ref27","unstructured":"Brier MR , Gordon B , Friedrichsen K , McCarthy J , Stern A , Christensen J , Owen C , Aldea P , Su Y , Hassenstab J , Cairns NJ , Holtzman DM , Fagan AM , Morris JC , Benzinger TL , Ances BM (2016) Tau and Abeta imaging, CSF measures, and cognition in Alzheimer\u2019s disease. Sci Transl Med 8, 338ra366."},{"key":"10.3233\/JAD-170129_ref28","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1212\/WNL.0000000000003050","article-title":"Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly","volume":"87","author":"Chhatwal","year":"2016","journal-title":"Neurology"},{"key":"10.3233\/JAD-170129_ref29","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-170129_ref30","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.neuroimage.2010.06.044","article-title":"Imaging dopamine receptors in humans with [11C]-(+)-PHNO: Dissection of D3 signal and anatomy","volume":"54","author":"Tziortzi","year":"2011","journal-title":"Neuroimage"},{"key":"10.3233\/JAD-170129_ref31","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0197-4580(95)00021-6","article-title":"Staging of Alzheimer\u2019s disease-related neurofibrillary changes","volume":"16","author":"Braak","year":"1995","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-170129_ref32","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrneurol.2010.4","article-title":"Cerebrospinal fluid and plasma biomarkers in Alzheimer disease","volume":"6","author":"Blennow","year":"2010","journal-title":"Nat Rev Neurol"},{"key":"10.3233\/JAD-170129_ref33","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1001\/jamaneurol.2014.1358","article-title":"Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid beta-amyloid 42: A cross-validation study against amyloid positron emission tomography","volume":"71","author":"Palmqvist","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.3233\/JAD-170129_ref34","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/ana.24546","article-title":"Tau positron emission tomographic imaging in aging and early Alzheimer disease","volume":"79","author":"Johnson","year":"2016","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-170129_ref35","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/j.neurobiolaging.2014.03.009","article-title":"Medial temporal atrophy in early and late-onset Alzheimer\u2019s disease","volume":"35","author":"Cavedo","year":"2014","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-170129_ref36","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1177\/1533317512454711","article-title":"Nonamnestic presentations of early-onset Alzheimer\u2019s disease","volume":"27","author":"Mendez","year":"2012","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"10.3233\/JAD-170129_ref37","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1016\/j.neurobiolaging.2013.02.013","article-title":"Different patterns of gray matter atrophy in early- and late-onset Alzheimer\u2019s disease","volume":"34","author":"Moller","year":"2013","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-170129_ref38","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3233\/JAD-2012-111934","article-title":"Early onset Alzheimer\u2019s disease is associated with a distinct neuropsychological profile","volume":"30","author":"Smits","year":"2012","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-170129_ref39","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S1474-4422(11)70156-9","article-title":"Neuropathologically defined subtypes of Alzheimer\u2019s disease with distinct clinical characteristics: A retrospective study","volume":"10","author":"Murray","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-170129_ref40","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1017\/S0033291709005492","article-title":"Most rapid cognitive decline in APOE epsilon4 negative Alzheimer\u2019s disease with early onset","volume":"39","author":"van der Vlies","year":"2009","journal-title":"Psychol Med"},{"key":"10.3233\/JAD-170129_ref41","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1212\/WNL.44.7.1215","article-title":"Age at onset of Alzheimer\u2019s disease: Relation to pattern of cognitive dysfunction and rate of decline","volume":"44","author":"Jacobs","year":"1994","journal-title":"Neurology"},{"key":"10.3233\/JAD-170129_ref42","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3389\/fneur.2015.00186","article-title":"Fluid biomarkers in clinical trials of Alzheimer\u2019s disease therapeutics","volume":"6","author":"Ritter","year":"2015","journal-title":"Front Neurol"},{"key":"10.3233\/JAD-170129_ref43","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1093\/brain\/aww139","article-title":"The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging","volume":"139","author":"Gordon","year":"2016","journal-title":"Brain"},{"key":"10.3233\/JAD-170129_ref44","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0b013e3182840bbe","article-title":"Brain beta-amyloid load approaches a plateau","volume":"80","author":"Jack","year":"2013","journal-title":"Neurology"},{"key":"10.3233\/JAD-170129_ref45","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/emmm.200900048","article-title":"Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer\u2019s disease","volume":"1","author":"Fagan","year":"2009","journal-title":"EMBO Mol Med"},{"key":"10.3233\/JAD-170129_ref46","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.tips.2015.03.002","article-title":"Amyloid biomarkers in Alzheimer\u2019s disease","volume":"36","author":"Blennow","year":"2015","journal-title":"Trends Pharmacol Sci"},{"key":"10.3233\/JAD-170129_ref47","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1001\/jamaneurol.2013.5847","article-title":"Amyloid-beta and tau: The trigger and bullet in Alzheimer disease pathogenesis","volume":"71","author":"Bloom","year":"2014","journal-title":"JAMA Neurol"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-170129","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:04:42Z","timestamp":1777370682000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-170129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,29]]},"references-count":47,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.3233\/jad-170129","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,29]]}}}